Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib and Dexamethasone

1) A method of improving overall response rate (ORR) in a subject or a population of subjects with multiple myeloma, said method comprising subcutaneously administering to the subject or the population of subjects a pharmaceutical composition in combination with bortezomib and dexamethasone, wherein said pharmaceutical composition comprises:

• • an antibody that specifically binds CD38 and comprises a heavy chain complementarity determining region 1 (HCDR1) of SEQ ID NO:
• 1, a HCDR2 of SEQ ID NO:
• 2, a HCDR3 of SEQ ID NO:
• 3, a light chain complementarity determining region 1 (LCDR1) of SEQ ID NO:
• 4, a LCDR2 of SEQ ID NO:
• 5 and a LCDR3 of SEQ ID NO:
• 6, and
• • recombinant human hyaluronidase (rHuPH20),
• wherein the improvement in ORR is relative to ORR of a reference population of subjects with multiple myeloma, said reference population having been administered said pharmaceutical composition but not bortezomib and dexamethasone.